Indirect treatment comparison and cost-minimization analysis of riociguat versus selexipag in patients with pulmonary arterial hypertension.

Eva Ornstová Jan Tuzil Kateřina Chadimová Tomas MlcochTomáš Doležal

Published in: Expert review of pharmacoeconomics & outcomes research (2022)

Switching to riociguat represents the cost-saving therapy for PAH patients who were inadequately compensated with the PDE5i+ERA therapy. Consequently, riociguat has been introduced to the list of reimbursed medicines in Czechia from October 2021. Based on two global trials, we prepared the first indirect treatment comparison followed with CMA of these therapies that may improve future decision-making for PAH indications.

Keyphrases

pulmonary arterial hypertension
pulmonary hypertension
pulmonary artery
decision making
stem cells
bone marrow